Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1571 USD | -4.21% | -10.94% | -13.68% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Mar. 29 | Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2022 | 25.9M | Sales 2023 | 42.81M | Capitalization | 17.99M |
---|---|---|---|---|---|
Net income 2022 | -33M | Net income 2023 | -24M | EV / Sales 2022 | 1.21 x |
Net cash position 2022 | 46.07M | Net cash position 2023 | 26.37M | EV / Sales 2023 | -0.2 x |
P/E ratio 2022 |
-2.32
x | P/E ratio 2023 |
-0.67
x | Employees | 48 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.57% |
Latest transcript on Pieris Pharmaceuticals, Inc.
1 day | -4.21% | ||
1 week | -10.94% | ||
Current month | -14.25% | ||
1 month | -25.19% | ||
3 months | -5.65% | ||
6 months | -40.33% | ||
Current year | -13.68% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 09-12-31 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 17-11-30 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 16-09-19 | |
James Geraghty
CHM | Chairman | 70 | 17-05-21 |
Michael Richman
BRD | Director/Board Member | 63 | 14-12-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-16 | 0.164 | -3.53% | 320,624 |
24-04-15 | 0.17 | -1.01% | 562,128 |
24-04-12 | 0.1717 | -2.65% | 233,222 |
24-04-11 | 0.1764 | -0.51% | 245,460 |
24-04-10 | 0.1773 | -2.48% | 279,678 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-13.68% | 16.23M | |
-3.39% | 102B | |
+2.61% | 96.09B | |
-1.02% | 22.05B | |
-18.14% | 20.81B | |
-6.87% | 19.06B | |
-40.70% | 16.05B | |
-26.89% | 14.01B | |
+1.12% | 13.38B | |
+22.25% | 11.01B |
- Stock Market
- Equities
- PIRS Stock